American Institute of Mathematical Sciences

Advanced
June  2013, 18(4): 1031-1051. doi: 10.3934/dcdsb.2013.18.1031

Optimal controls for a mathematical model of tumor-immune interactions under targeted chemotherapy with immune boost

Urszula Ledzewicz 1, , Mozhdeh Sadat Faraji Mosalman 1, and  Heinz Schättler 2,

1. 

Dept. of Mathematics and Statistics, Southern Illinois University Edwardsville, Edwardsville, Illinois, 62026-1653, United States
2. 

Dept. of Electrical and Systems Engineering, Washington University, St. Louis, Missouri, 63130-4899

Received  December 2011 Revised  April 2012 Published  February 2013

An optimal control problem for combination of cancer chemotherapy with immunotherapy in form of a boost to the immune system is considered as a multi-input optimal control problem. The objective to be minimized is chosen as a weighted average of (i) the number of cancer cells at the terminal time, (ii) a measure for the immunocompetent cell densities at the terminal point (included as a negative term), the overall amounts of (iii) cytotoxic agents and (iv) immune boost given as a measure for the side effects of treatment and (v) a small penalty on the free terminal time that limits the overall therapy horizon. This last term is essential in obtaining a mathematically well-posed problem formulation. Both analytical and numerical results about the structures of optimal controls will be presented that give some insights into the structure of optimal protocols, i.e., the dose rates and sequencing of drugs in these combination treatments.
Keywords: singular controls, tumor-immune interactions, Optimal control, regions of attraction., chemotherapy.
Mathematics Subject Classification: Primary: 49K15, 92B05; Secondary: 93C9.
Citation: Urszula Ledzewicz, Mozhdeh Sadat Faraji Mosalman, Heinz Schättler. Optimal controls for a mathematical model of tumor-immune interactions under targeted chemotherapy with immune boost. Discrete and Continuous Dynamical Systems - B, 2013, 18 (4) : 1031-1051. doi: 10.3934/dcdsb.2013.18.1031
References:
[1]

D. J. Bell and D. H. Jacobson, "Singular Optimal Control Problems," Academic Press, 1975.

[2]

D. A. Benson, "A Gauss Pseudospectral Transcription for Optimal Control," Ph.D. thesis, MIT, 2004.

[3]

D. A. Benson, G. T. Huntington, T. P. Thorvaldsen and A. V. Rao, Direct trajectory optimization and costate estimation via an orthogonal collocation method, J. of Guidance, Control, and Dynamics, 29 (2006), 1435-1440.

[4]

B. Bonnard and M. Chyba, "Singular Trajectories and their Role in Control Theory," Springer Verlag, Series: Mathematics and Applications, Vol. 40, 2003.

[5]

A. Bressan and B. Piccoli, "Introduction to the Mathematical Theory of Control," American Institute of Mathematical Sciences, 2007.

[6]

T. Burden, J. Ernstberger and K. R. Fister, Optimal control applied to immunotherapy Discrete and Continuous Dynamical Systems - Series B, 4 (2004), 135-146.

[7]

F. Castiglione and B. Piccoli, Optimal control in a model of dendritic cell transfection cancer immunotherapy, Bulletin of Mathematical Biology, 68 (2006), 255-274. doi: 10.1007/s11538-005-9014-3.

[8]

M. Eisen, "Mathematical Models in Cell Biology and Cancer Chemotherapy," Lecture Notes in Biomathematics, Vol. 30, Springer Verlag, 1979.

[9]

A. Ergun, K. Camphausen and L. M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bulletin of Mathematical Biology, 65 (2003), 407-424.

[10]

K. R. Fister and J. Hughes Donnelly, Immunotherapy: an optimal control approach, Mathematical Biosciences and Engineering (MBE), 2 2005, 499-510. doi: 10.3934/mbe.2005.2.499.

[11]

J. Guckenheimer and P. Holmes, "Nonlinear Oscillations, Dynamical Systems, and Bifurcations of Vector Fields," Springer Verlag, New York, 1983.

[12]

G. T. Huntington, "Advancement and Analysis of a Gauss Pseudospectral Transcription for Optimal Control," Ph.D. thesis, MIT, 2007.

[13]

D. Kirschner and J. C. Panetta, Modeling immunotherapy of the tumor-immune interaction, J. of Mathematical Biology, 37 (1998), 235-252.

[14]

V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis, Bull. Mathematical Biology, 56 (1994), 295-321.

[15]

U. Ledzewicz, J. Marriott, H. Maurer and H. Schättler, Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment, Math. Medicine and Biology, 27 (2010), 157-179. doi: 10.1093/imammb/dqp012.

[16]

U. Ledzewicz, H. Maurer and H. Schättler, Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments, Proc. 48th IEEE Conf. on Dec. and Contr., Shanghai, China, (2009), 2280-2285.

[17]

U. Ledzewicz, M. Naghnaeian and H. Schättler, An optimal control approach to cancer treatment under immunological activity, Applicationes Mathematicae, 38 (2011), 17-31. doi: 10.4064/am38-1-2.

[18]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Bifurcation of singular arcs in an optimal control problem for cancer immune system interactions under treatment, Proceedings of the 49th IEEE Conf. on Decision and Control, Atlanta, USA, (2010), 7039-7044.

[19]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Dynamics of tumor-immune interactions under treatment as an optimal control problem, Proc. of the 8th AIMS Conf., Dresden, Germany, (2010), 971-980.

[20]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics, J. of Mathematical Biology, 64 (2012), 557-577. doi: 10.1007/s00285-011-0424-6.

[21]

U. Ledzewicz and H. Schättler, Analysis of a cell-cycle specific model for cancer chemotherapy, J. of Biological Systems, 10 (2002), 183-206.

[22]

U. Ledzewicz and H. Schättler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. Control and Optimization, 46 (2007), 1052-1079. doi: 10.1137/060665294.

[23]

U. Ledzewicz and H. Schättler, Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis, J. of Theoretical Biology, 252 (2008), 295-312.

[24]

L. Norton and R. Simon, Growth curve of an experimental solid tumor following radiotherapy, J. of the National Cancer Institute, 58 (1977), 1735-1741.

[25]

L. Norton, A Gompertzian model of human breast cancer growth, Cancer Research, 48 (1988), 7067-7071.

[26]

A. d'Onofrio, A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences, Physica D, 208 (2005), 220-235 doi: 10.1016/j.physd.2005.06.032.

[27]

A. d'Onofrio, Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy, Math. Models and Methods in Applied Sciences, 16 (2006), 1375-1401. doi: 10.1142/S0218202506001571.

[28]

A. d'Onofrio, U. Ledzewicz, H. Maurer and H. Schättler, On Optimal Delivery of Combination Therapy for Tumors, Mathematical Biosciences, 222 (2009), 13-26. doi: 10.1016/j.mbs.2009.08.004.

[29]

L. G. de Pillis and A. Radunskaya, A mathematical tumor model with immune resistance and drug therapy: an optimal control approach, J. of Theoretical Medicine, 3 (2001), 79-100.

[30]

A. V. Rao, D. A. Benson, G. T. Huntington, C. Francolin, C. L. Darby and M. A. Patterson, "User's Manual for GPOPS: A MATLAB Package for Dynamic Optimization Using the Gauss Pseudospectral Method," University of Florida Report, 2008.

[31]

H. Schättler and U. Ledzewicz, "Geometric Optimal Control: Theory, Methods and Examples," Springer Verlag, 2012. doi: 10.1007/978-1-4614-3834-2.

[32]

N.V. Stepanova, Course of the immune reaction during the development of a malignant tumour, Biophysics, 24 (1980), 917-923.

[33]

G. W. Swan, Role of optimal control in cancer chemotherapy, Mathematical Biosciences, 101 (1990), 237-284.

[34]

A. Swierniak, Optimal treatment protocols in leukemia - modelling the proliferation cycle, Proceedings of the 12th IMACS World Congress, Paris, 4 (1988), 170-172.

[35]

A. Swierniak, Cell cycle as an object of control, J. of Biological Systems, 3 (1995), 41-54.

[36]

A. Swierniak, U. Ledzewicz and H. Schättler, Optimal control for a class of compartmental models in cancer chemotherapy, Int. J. Applied Mathematics and Computer Science, 13 (2003), 357-368.

[37]

H. P. de Vladar and J. A. González, Dynamic response of cancer under the influence of immunological activity and therapy, J. of Theoretical Biology, 227 (2004), 335-348. doi: 10.1016/j.jtbi.2003.11.012.

show all references

References:
[1]

D. J. Bell and D. H. Jacobson, "Singular Optimal Control Problems," Academic Press, 1975.

[2]

D. A. Benson, "A Gauss Pseudospectral Transcription for Optimal Control," Ph.D. thesis, MIT, 2004.

[3]

D. A. Benson, G. T. Huntington, T. P. Thorvaldsen and A. V. Rao, Direct trajectory optimization and costate estimation via an orthogonal collocation method, J. of Guidance, Control, and Dynamics, 29 (2006), 1435-1440.

[4]

B. Bonnard and M. Chyba, "Singular Trajectories and their Role in Control Theory," Springer Verlag, Series: Mathematics and Applications, Vol. 40, 2003.

[5]

A. Bressan and B. Piccoli, "Introduction to the Mathematical Theory of Control," American Institute of Mathematical Sciences, 2007.

[6]

T. Burden, J. Ernstberger and K. R. Fister, Optimal control applied to immunotherapy Discrete and Continuous Dynamical Systems - Series B, 4 (2004), 135-146.

[7]

F. Castiglione and B. Piccoli, Optimal control in a model of dendritic cell transfection cancer immunotherapy, Bulletin of Mathematical Biology, 68 (2006), 255-274. doi: 10.1007/s11538-005-9014-3.

[8]

M. Eisen, "Mathematical Models in Cell Biology and Cancer Chemotherapy," Lecture Notes in Biomathematics, Vol. 30, Springer Verlag, 1979.

[9]

A. Ergun, K. Camphausen and L. M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bulletin of Mathematical Biology, 65 (2003), 407-424.

[10]

K. R. Fister and J. Hughes Donnelly, Immunotherapy: an optimal control approach, Mathematical Biosciences and Engineering (MBE), 2 2005, 499-510. doi: 10.3934/mbe.2005.2.499.

[11]

J. Guckenheimer and P. Holmes, "Nonlinear Oscillations, Dynamical Systems, and Bifurcations of Vector Fields," Springer Verlag, New York, 1983.

[12]

G. T. Huntington, "Advancement and Analysis of a Gauss Pseudospectral Transcription for Optimal Control," Ph.D. thesis, MIT, 2007.

[13]

D. Kirschner and J. C. Panetta, Modeling immunotherapy of the tumor-immune interaction, J. of Mathematical Biology, 37 (1998), 235-252.

[14]

V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis, Bull. Mathematical Biology, 56 (1994), 295-321.

[15]

U. Ledzewicz, J. Marriott, H. Maurer and H. Schättler, Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment, Math. Medicine and Biology, 27 (2010), 157-179. doi: 10.1093/imammb/dqp012.

[16]

U. Ledzewicz, H. Maurer and H. Schättler, Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments, Proc. 48th IEEE Conf. on Dec. and Contr., Shanghai, China, (2009), 2280-2285.

[17]

U. Ledzewicz, M. Naghnaeian and H. Schättler, An optimal control approach to cancer treatment under immunological activity, Applicationes Mathematicae, 38 (2011), 17-31. doi: 10.4064/am38-1-2.

[18]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Bifurcation of singular arcs in an optimal control problem for cancer immune system interactions under treatment, Proceedings of the 49th IEEE Conf. on Decision and Control, Atlanta, USA, (2010), 7039-7044.

[19]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Dynamics of tumor-immune interactions under treatment as an optimal control problem, Proc. of the 8th AIMS Conf., Dresden, Germany, (2010), 971-980.

[20]

U. Ledzewicz, M. Naghnaeian and H. Schättler, Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics, J. of Mathematical Biology, 64 (2012), 557-577. doi: 10.1007/s00285-011-0424-6.

[21]

U. Ledzewicz and H. Schättler, Analysis of a cell-cycle specific model for cancer chemotherapy, J. of Biological Systems, 10 (2002), 183-206.

[22]

U. Ledzewicz and H. Schättler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. Control and Optimization, 46 (2007), 1052-1079. doi: 10.1137/060665294.

[23]

U. Ledzewicz and H. Schättler, Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis, J. of Theoretical Biology, 252 (2008), 295-312.

[24]

L. Norton and R. Simon, Growth curve of an experimental solid tumor following radiotherapy, J. of the National Cancer Institute, 58 (1977), 1735-1741.

[25]

L. Norton, A Gompertzian model of human breast cancer growth, Cancer Research, 48 (1988), 7067-7071.

[26]

A. d'Onofrio, A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences, Physica D, 208 (2005), 220-235 doi: 10.1016/j.physd.2005.06.032.

[27]

A. d'Onofrio, Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy, Math. Models and Methods in Applied Sciences, 16 (2006), 1375-1401. doi: 10.1142/S0218202506001571.

[28]

A. d'Onofrio, U. Ledzewicz, H. Maurer and H. Schättler, On Optimal Delivery of Combination Therapy for Tumors, Mathematical Biosciences, 222 (2009), 13-26. doi: 10.1016/j.mbs.2009.08.004.

[29]

L. G. de Pillis and A. Radunskaya, A mathematical tumor model with immune resistance and drug therapy: an optimal control approach, J. of Theoretical Medicine, 3 (2001), 79-100.

[30]

A. V. Rao, D. A. Benson, G. T. Huntington, C. Francolin, C. L. Darby and M. A. Patterson, "User's Manual for GPOPS: A MATLAB Package for Dynamic Optimization Using the Gauss Pseudospectral Method," University of Florida Report, 2008.

[31]

H. Schättler and U. Ledzewicz, "Geometric Optimal Control: Theory, Methods and Examples," Springer Verlag, 2012. doi: 10.1007/978-1-4614-3834-2.

[32]

N.V. Stepanova, Course of the immune reaction during the development of a malignant tumour, Biophysics, 24 (1980), 917-923.

[33]

G. W. Swan, Role of optimal control in cancer chemotherapy, Mathematical Biosciences, 101 (1990), 237-284.

[34]

A. Swierniak, Optimal treatment protocols in leukemia - modelling the proliferation cycle, Proceedings of the 12th IMACS World Congress, Paris, 4 (1988), 170-172.

[35]

A. Swierniak, Cell cycle as an object of control, J. of Biological Systems, 3 (1995), 41-54.

[36]

A. Swierniak, U. Ledzewicz and H. Schättler, Optimal control for a class of compartmental models in cancer chemotherapy, Int. J. Applied Mathematics and Computer Science, 13 (2003), 357-368.

[37]

H. P. de Vladar and J. A. González, Dynamic response of cancer under the influence of immunological activity and therapy, J. of Theoretical Biology, 227 (2004), 335-348. doi: 10.1016/j.jtbi.2003.11.012.

[1]

Urszula Ledzewicz, Omeiza Olumoye, Heinz Schättler. On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth. Mathematical Biosciences & Engineering, 2013, 10 (3) : 787-802. doi: 10.3934/mbe.2013.10.787
[2]

Urszula Ledzewicz, Mohammad Naghnaeian, Heinz Schättler. Dynamics of tumor-immune interaction under treatment as an optimal control problem. Conference Publications, 2011, 2011 (Special) : 971-980. doi: 10.3934/proc.2011.2011.971
[3]

Sophia R-J Jang, Hsiu-Chuan Wei. On a mathematical model of tumor-immune system interactions with an oncolytic virus therapy. Discrete and Continuous Dynamical Systems - B, 2022, 27 (6) : 3261-3295. doi: 10.3934/dcdsb.2021184
[4]

Shuo Wang, Heinz Schättler. Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity. Mathematical Biosciences & Engineering, 2016, 13 (6) : 1223-1240. doi: 10.3934/mbe.2016040
[5]

Shujing Shi, Jicai Huang, Yang Kuang. Global dynamics in a tumor-immune model with an immune checkpoint inhibitor. Discrete and Continuous Dynamical Systems - B, 2021, 26 (2) : 1149-1170. doi: 10.3934/dcdsb.2020157
[6]

Dan Liu, Shigui Ruan, Deming Zhu. Bifurcation analysis in models of tumor and immune system interactions. Discrete and Continuous Dynamical Systems - B, 2009, 12 (1) : 151-168. doi: 10.3934/dcdsb.2009.12.151
[7]

Giulio Caravagna, Alex Graudenzi, Alberto d’Onofrio. Distributed delays in a hybrid model of tumor-Immune system interplay. Mathematical Biosciences & Engineering, 2013, 10 (1) : 37-57. doi: 10.3934/mbe.2013.10.37
[8]

J.C. Arciero, T.L. Jackson, D.E. Kirschner. A mathematical model of tumor-immune evasion and siRNA treatment. Discrete and Continuous Dynamical Systems - B, 2004, 4 (1) : 39-58. doi: 10.3934/dcdsb.2004.4.39
[9]

Shigui Ruan. Nonlinear dynamics in tumor-immune system interaction models with delays. Discrete and Continuous Dynamical Systems - B, 2021, 26 (1) : 541-602. doi: 10.3934/dcdsb.2020282
[10]

Mohammad A. Tabatabai, Wayne M. Eby, Karan P. Singh, Sejong Bae. T model of growth and its application in systems of tumor-immune dynamics. Mathematical Biosciences & Engineering, 2013, 10 (3) : 925-938. doi: 10.3934/mbe.2013.10.925
[11]

Lifeng Han, Changhan He, Yang Kuang. Dynamics of a model of tumor-immune interaction with time delay and noise. Discrete and Continuous Dynamical Systems - S, 2020, 13 (9) : 2347-2363. doi: 10.3934/dcdss.2020140
[12]

Gladis Torres-Espino, Claudio Vidal. Periodic solutions of a tumor-immune system interaction under a periodic immunotherapy. Discrete and Continuous Dynamical Systems - B, 2021, 26 (8) : 4523-4547. doi: 10.3934/dcdsb.2020301
[13]

Shuo Wang, Heinz Schättler. Optimal control for cancer chemotherapy under tumor heterogeneity with Michealis-Menten pharmacodynamics. Discrete and Continuous Dynamical Systems - B, 2019, 24 (5) : 2383-2405. doi: 10.3934/dcdsb.2019100
[14]

Arturo Alvarez-Arenas, Konstantin E. Starkov, Gabriel F. Calvo, Juan Belmonte-Beitia. Ultimate dynamics and optimal control of a multi-compartment model of tumor resistance to chemotherapy. Discrete and Continuous Dynamical Systems - B, 2019, 24 (5) : 2017-2038. doi: 10.3934/dcdsb.2019082
[15]

Urszula Ledzewicz, Heinz Schättler, Shuo Wang. On the role of tumor heterogeneity for optimal cancer chemotherapy. Networks and Heterogeneous Media, 2019, 14 (1) : 131-147. doi: 10.3934/nhm.2019007
[16]

Jianquan Li, Xin Xie, Dian Zhang, Jia Li, Xiaolin Lin. Qualitative analysis of a simple tumor-immune system with time delay of tumor action. Discrete and Continuous Dynamical Systems - B, 2021, 26 (10) : 5227-5249. doi: 10.3934/dcdsb.2020341
[17]

Jianquan Li, Xiangxiang Ma, Yuming Chen, Dian Zhang. Complex dynamic behaviors of a tumor-immune system with two delays in tumor actions. Discrete and Continuous Dynamical Systems - B, 2022  doi: 10.3934/dcdsb.2022033
[18]

Martina Conte, Maria Groppi, Giampiero Spiga. Qualitative analysis of kinetic-based models for tumor-immune system interaction. Discrete and Continuous Dynamical Systems - B, 2018, 23 (6) : 2393-2414. doi: 10.3934/dcdsb.2018060
[19]

Min Yu, Gang Huang, Yueping Dong, Yasuhiro Takeuchi. Complicated dynamics of tumor-immune system interaction model with distributed time delay. Discrete and Continuous Dynamical Systems - B, 2020, 25 (7) : 2391-2406. doi: 10.3934/dcdsb.2020015
[20]

Urszula Ledzewicz, Heinz Schättler. The Influence of PK/PD on the Structure of Optimal Controls in Cancer Chemotherapy Models. Mathematical Biosciences & Engineering, 2005, 2 (3) : 561-578. doi: 10.3934/mbe.2005.2.561

2020 Impact Factor: 1.327

Tools

Metrics

  • PDF downloads (354)
  • HTML views (0)
  • Cited by (23)

Other articles
by authors

[Back to Top]

Copyright © 2022 American Institute of Mathematical Sciences | Privacy Policy